Coronado Biosciences, Inc. (CNDO)
-NasdaqCM 7.98 
0.76(8.70%) 2:59PM EDT - Nasdaq Real Time Price
| Prev Close: | 8.74 |
|---|
| Open: | 8.71 |
|---|
| Bid: | 8.08 x 300 |
|---|
| Ask: | 8.12 x 400 |
|---|
| 1y Target Est: | 16.79 |
|---|
| Beta: | 3.603 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 7.98 - 8.76 |
|---|
| 52wk Range: | 4.00 - 12.70 |
|---|
| Volume: | 353,082 |
|---|
| Avg Vol (3m): | 370,438 |
|---|
| Market Cap: | 223.82M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.28 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why Coronado Biosciences Is Poised to Keep Plungingat Motley Fool(Mon, Jun 17)
- When It Comes To Biotech, Diversity Is Keyat Seeking Alpha(Wed, Jun 12)
- Coronado Biosciences Appoints George Avgerinos, Ph.D. as Senior Vice President, Biologics OperationsGlobeNewswire(Tue, Jun 4)
- CORONADO BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Jun 4)
- Record Use of At-the-Market (ATM) Offerings Continues in 2013 with $161 Million Raised by U.S. Life Sciences Companies in First Quarter, Reports Brinson PatrickPR Newswire(Tue, May 28)
- Coronado Biosciences to Present at the Jefferies 2013 Global Healthcare ConferenceGlobeNewswire(Tue, May 28)
- [video] Options Activity Ahead of Pandora Earningsat CNBC(Thu, May 23)
- [video] Nasdaq Check: Tech Stocks Recoverat CNBC(Thu, May 23)
- CORONADO BIOSCIENCES INC FinancialsEDGAR Online Financials(Fri, May 17)
- Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care InnovationWall Street Transcript(Thu, May 16)
- CORONADO BIOSCIENCES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Coronado Biosciences' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2013GlobeNewswire(Wed, May 8)
- Q1 2013 Coronado Biosciences Earnings Release - Before Market OpenCCBN(Wed, May 8)
- CORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.31 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.32 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Coronado Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.
View More